PURPOSE: To investigate the possibility of measuring the gene-specific DNA damage after therapeutic exposure to nitrogen mustards and to examine its relationship with the clinical response. EXPERIMENTAL DESIGN: The kinetics of gene-specific monoadducts and interstrand cross-link formation/repair were measured in the p53 and N-ras genes. DNA extracted from human peripheral lymphocytes following in vitro exposure to melphalan or therapeutic exposure to melphalan or cyclophosphamide was used. RESULTS: When lymphocytes were treated in vitro with biologically relevant doses of melphalan, monoadducts accumulated rapidly in both p53 and N-ras genes, reaching maximal levels within 2 h, whereas the highest interstrand cross-link levels were found within 8 h. Thereafter, the adducts were repaired with half-lives of 14.5 +/- 0.3 h (p53) or 18.8 +/- 1.5 h (N-ras) for monoadducts and 12.4 +/- 0.8 h (p53) or 14.1 +/- 2.2 h (N-ras) for interstrand cross-links. Moreover, peak levels of monoadducts in both genes were observed 2 h after treatment in peripheral leukocytes from patients with multiple myeloma treated with high-dose i.v. melphalan, supported by autologous stem cell transplantation, whereas interstrand cross-links were maximal within 8 h. Of seven patients examined, the three who showed the least levels of DNA damage did not respond to the high-dose melphalan. CONCLUSIONS: This is the first report showing that it is feasible to measure gene-specific DNA damage in a readily accessible tissue of humans exposed to bifunctional alkylating drugs and to examine, at the level of the individual patient, the relationships between the induction/repair of cytotoxic DNA damage and clinical response or long-term complications.
PURPOSE: To investigate the possibility of measuring the gene-specific DNA damage after therapeutic exposure to nitrogen mustards and to examine its relationship with the clinical response. EXPERIMENTAL DESIGN: The kinetics of gene-specific monoadducts and interstrand cross-link formation/repair were measured in the p53 and N-ras genes. DNA extracted from human peripheral lymphocytes following in vitro exposure to melphalan or therapeutic exposure to melphalan or cyclophosphamide was used. RESULTS: When lymphocytes were treated in vitro with biologically relevant doses of melphalan, monoadducts accumulated rapidly in both p53 and N-ras genes, reaching maximal levels within 2 h, whereas the highest interstrand cross-link levels were found within 8 h. Thereafter, the adducts were repaired with half-lives of 14.5 +/- 0.3 h (p53) or 18.8 +/- 1.5 h (N-ras) for monoadducts and 12.4 +/- 0.8 h (p53) or 14.1 +/- 2.2 h (N-ras) for interstrand cross-links. Moreover, peak levels of monoadducts in both genes were observed 2 h after treatment in peripheral leukocytes from patients with multiple myeloma treated with high-dose i.v. melphalan, supported by autologous stem cell transplantation, whereas interstrand cross-links were maximal within 8 h. Of seven patients examined, the three who showed the least levels of DNA damage did not respond to the high-dose melphalan. CONCLUSIONS: This is the first report showing that it is feasible to measure gene-specific DNA damage in a readily accessible tissue of humans exposed to bifunctional alkylating drugs and to examine, at the level of the individual patient, the relationships between the induction/repair of cytotoxic DNA damage and clinical response or long-term complications.
Authors: M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis Journal: Leukemia Date: 2013-10-03 Impact factor: 11.528
Authors: L'Aurelle A Johnson; Bhaskar Malayappan; Natalia Tretyakova; Colin Campbell; Margaret L MacMillan; John E Wagner; Pamala A Jacobson Journal: Pediatr Blood Cancer Date: 2011-07-25 Impact factor: 3.167
Authors: Maria Gkotzamanidou; Evangelos Terpos; Christina Bamia; Nikhil C Munshi; Meletios A Dimopoulos; Vassilis L Souliotis Journal: Blood Date: 2016-07-21 Impact factor: 22.113
Authors: David C Johnson; Sophie Corthals; Christine Ramos; Antje Hoering; Kim Cocks; Nicholas J Dickens; Jeff Haessler; Harmut Goldschmidt; J Anthony Child; Sue E Bell; Graham Jackson; Dalsu Baris; S Vincent Rajkumar; Faith E Davies; Brian G M Durie; John Crowley; Pieter Sonneveld; Brian Van Ness; Gareth J Morgan Journal: Blood Date: 2008-09-19 Impact factor: 22.113
Authors: M Gkotzamanidou; P P Sfikakis; S A Kyrtopoulos; C Bamia; M A Dimopoulos; V L Souliotis Journal: Br J Cancer Date: 2014-07-22 Impact factor: 7.640